Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow KLRA by emailGet an email when KLRA pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about KLRA, unsubscribe in one click. Privacy
📣 What KLRA Says Is Next
first half of 2027 · “Investigational New Drug (IND) application active with U.S. FDA: With an active IND, Kailera remains on track to initiate planned global Phase 3 trials in obesity in the first half of 2027.”
Company press release, Aug 12, 2026 · SEC filing
mid-2027 · “Data are anticipated in mid-2027.”
Company press release, Aug 12, 2026 · SEC filing
in 2028 · “Enrollment on track in global Phase 3 KaiNETIC program with data anticipated in 2028: The program encompasses three global, double-blind, randomized, placebo-controlled Phase 3 trials (KaiNETIC-1, NCT07284875; KaiNETIC-2, NCT07284901; KaiNETIC-3, NCT07284979) enrolling more than 4,700 participants.”
Company press release, Aug 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full KLRA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KLRA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.